Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.

NCT01619865 is registered in ClinicalTrials.gov with Sue O'Dorisio as lead sponsor.

NCT NCT01619865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01619865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.
Lead sponsor
Sue O'Dorisio
Phase
Phase 1/2
Overall status
Completed
Start date
February 21, 2012
Completion date
August 27, 2017
Enrollment
223 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid tumors, medulloblastoma, neuroblastoma, neuroendocrine tumors